A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
- PMID: 16054802
- DOI: 10.1016/j.schres.2005.06.015
A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
Abstract
Background: Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term.
Method: This retrospective analysis of data from a 28-week, double-blind, schizophrenia trial compared the cumulative amount of time that patients met severity criteria for remission during olanzapine (10-20 mg/day) or risperidone (4-12 mg/day) treatment.
Results: The percentage cumulative time spent in remission was 40% for olanzapine- and 31% for risperidone-treated patients (P = 0.03) using Definition 1 (PANSS items P1, P2, P3, N1, N4, N6, G5, G9 < or = 3), and 18% and 11% (P = 0.01), respectively, using Definition 2 (BPRS Total reduced 50%, BPRS psychosis items < or = 3, CGI-severity < or = 3).
Conclusion: During 28 weeks of treatment, olanzapine-treated patients spent more cumulative time in remission than risperidone-treated patients.
Comment in
-
Measuring remission in schizophrenia: response to Sethuraman et al., 2005.Schizophr Res. 2006 Mar;83(1):109-10. doi: 10.1016/j.schres.2005.11.017. Epub 2006 Jan 19. Schizophr Res. 2006. PMID: 16423505 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
